Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.48 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182805 | 0.84 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPIP5K1C | |
| SCHEMBL30631164 | 0.84 | PIK3CA (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGPIP5K1C | |
| SCHEMBL182944 | 0.80 | SMN1; SMN2 (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL182718 | 0.80 | PIK3CD (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGPIP5K1C | |
| SCHEMBL182740 | 0.80 | MAP4K4 (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGPIP5K1C | |
| SCHEMBL180943 | 0.79 | ENPP1 (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGMAP4K4 | |
| SCHEMBL182967 | 0.78 | PIK3CA (0.68) | PIK3CDPIK3CAPIK3CBPIK3CGPIP5K1C | |
| SCHEMBL21219880 | 0.77 | ENPP1 (0.50) | — | |
| SCHEMBL182713 | 0.76 | PIK3CA (0.66) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL17845942 | 0.75 | RAF1 (0.71) | PIK3CDPIK3CAPIK3CBPIK3CGPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | disclosed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | disclosed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | disclosed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | PIK3CD 6/4885PIK3CA 3/4885PIK3CB 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.